Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.56 USD
+0.02 (0.59%)
Updated Aug 8, 2024 10:00 AM ET
After-Market: $2.61 +0.05 (1.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Armata Pharmaceuticals, Inc. [ARMP]
Reports for Purchase
Showing records 21 - 38 ( 38 total )
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Despite COVID-19 Setbacks, Clinical Pipeline Readies Strong Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; With Major Boost in Financing All Eyes on Key Clinical Trial Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Positioned Well for Important Phage Inflection Points; Target Upped to $
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; AP-PA02 Cleared to Begin Its Journey in Cystic Fibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; AP-PA02 Next Steps Coming Soon to Boost Excitement
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Heterologous E6/E7 Vaccine Now in the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; AP-PA02 Set to Enter the Clinic in 2020 to Address CF Airways Infections; Target Adjusted to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; AP-PA02 to Begin Clinical Development in 2020 on Solid Foundations; Target Adjusted to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Cash Infusion to Help With AP-PA02 CF Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Big Weight off Shares'' Shoulders; All Focus Can Be Placed on Clinical Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Preparations Ongoing in Earnest to Significantly Ramp up Clinical Activities
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Fine Tuning Strategy; Opportunities Remain Clear; Target Increased to $9.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Crucial Background Activities Ongoing Ahead of Clinical Transformation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Armata Has the Right Marching Orders; Highlights From KOL Event; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phage Strike One More Win Against Major Resistant Infection
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Welcome Armata; AmpliPhi and C3J Complete Merger to Form Phage Powerhouse; Target Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Armata Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Welcome Armata; AmpliPhi and C3J Complete Merger to Form Phage Powerhouse; Target Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J